Phosducin influences sympathetic activity and prevents stress-induced hypertension in humans and mice.
暂无分享,去创建一个
Stefan Lorkowski | Johanne Tremblay | Martin Biel | Ulrich Broeckel | Pavel Hamet | Lutz Hein | Monika Stoll | M. Barrot | M. Seeliger | D. Gaudet | S. Lorkowski | H. Jacob | M. Biel | U. Broeckel | M. Lohse | P. Hamet | J. Tremblay | M. Brede | O. Šeda | L. Hein | X. Zong | M. Stoll | T. Kotchen | A. Cowley | J. Kaufling | B. Szabo | Mary Kaldunski | Allen W Cowley | Daniel Gaudet | Howard J Jacob | Martin J Lohse | Nadine Beetz | R. Nüsing | M. Kaldunski | Theodore A Kotchen | Mathias W Seeliger | Nadine Beetz | Michael D Harrison | Marc Brede | Xiangang Zong | Michal J Urbanski | Anika Sietmann | Jennifer Kaufling | Michel Barrot | Maria Augusta Vieira-Coelho | Ondrej Seda | Rolf Nüsing | Bela Szabo | M. Vieira-Coelho | A. Sietmann | Michael D. Harrison | M. Urbanski | Jennifer Kaufling
[1] R. Langenbach,et al. Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse , 1995, Cell.
[2] H. Hamm,et al. Phosducin‐like protein acts as a molecular chaperone for G protein βγ dimer assembly , 2005 .
[3] Stefan Offermanns,et al. G12-G13–LARG–mediated signaling in vascular smooth muscle is required for salt-induced hypertension , 2008, Nature Medicine.
[4] S. E. Brodie. New York, New York, USA , 1996 .
[5] B. Obermaier,et al. Phosducin is a protein kinase A-regulated G-protein regulator , 1992, Nature.
[6] E. Antman,et al. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. , 2007, Circulation.
[7] R. Collins,et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies , 2002, The Lancet.
[8] R. Karas,et al. Regulator of G-protein signaling-2 mediates vascular smooth muscle relaxation and blood pressure , 2003, Nature Medicine.
[9] P. Guyenet. The sympathetic control of blood pressure , 2006, Nature Reviews Neuroscience.
[10] R. Victor,et al. Sympathetic neural mechanisms in human hypertension , 2008, Current hypertension reports.
[11] S. Gabriel,et al. The Structure of Haplotype Blocks in the Human Genome , 2002, Science.
[12] T. C. Janeway. The clinical study of blood-pressure : , 2009 .
[13] L Kruglyak,et al. Parametric and nonparametric linkage analysis: a unified multipoint approach. , 1996, American journal of human genetics.
[14] C. Craft,et al. Interaction of phosducin and phosducin isoforms with a 26S proteasomal subunit, SUG1. , 1998, Molecular vision.
[15] M. Lohse,et al. SUMO-1 Controls the Protein Stability and the Biological Function of Phosducin* , 2006, Journal of Biological Chemistry.
[16] P. Veinante,et al. Afferents to the GABAergic tail of the ventral tegmental area in the rat , 2009, The Journal of comparative neurology.
[17] B. Kobilka,et al. Two functionally distinct α2-adrenergic receptors regulate sympathetic neurotransmission , 1999, Nature.
[18] M. Esler,et al. The sympathetic system and hypertension. , 2000, American journal of hypertension.
[19] Marcia M. Nizzari,et al. Genome-Wide Association Analysis Identifies Loci for Type 2 Diabetes and Triglyceride Levels , 2007, Science.
[20] T. Hudson,et al. Quantitative founder-effect analysis of French Canadian families identifies specific loci contributing to metabolic phenotypes of hypertension. , 2005, American journal of human genetics.
[21] S. Neubauer,et al. Heterozygous alpha 2C-adrenoceptor-deficient mice develop heart failure after transverse aortic constriction. , 2007, Cardiovascular research.
[22] M. Seldin,et al. Rat pineal gland phosducin: cDNA isolation, nucleotide sequence, and chromosomal assignment in the mouse. , 1991, Genomics.
[23] I. Oshima,et al. Melatonin Content of the Pineal Gland in Different Mouse Strains , 1989, Journal of pineal research.
[24] P. V. van Haastert,et al. The Phosducin-Like Protein PhLP1 Is Essential for Gβγ Dimer Formation in Dictyostelium discoideum , 2005, Molecular and Cellular Biology.
[25] A. Cowley. The genetic dissection of essential hypertension , 2006, Nature Reviews Genetics.
[26] H. Krum,et al. Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. , 2005, Archives of internal medicine.
[27] G. Abecasis,et al. A general test of association for quantitative traits in nuclear families. , 2000, American journal of human genetics.
[28] J. Johnston,et al. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II , 1995, Nature.
[29] N. Schork,et al. Identification of Hypertension-Related QTLs in African American Sib Pairs , 2002, Hypertension.
[30] Robert J. Lefkowitz,et al. Seven-transmembrane-spanning receptors and heart function , 2002, Nature.
[31] L. Meinel,et al. Vascular Hypertrophy and Increased P70S6 Kinase in Mice Lacking the Angiotensin II AT2 Receptor , 2001, Circulation.
[32] Andrew Bohm,et al. Crystal Structure at 2.4 Å Resolution of the Complex of Transducin βγ and Its Regulator, Phosducin , 1996, Cell.
[33] M. Sokolov,et al. Phosducin Facilitates Light-driven Transducin Translocation in Rod Photoreceptors , 2004, Journal of Biological Chemistry.
[34] I. Llewellyn-Smith,et al. Neurochemistry of nerve fibers apposing sympathetic preganglionic neurons activated by sustained hypotension , 2002, The Journal of comparative neurology.
[35] M. Lohse,et al. Phosducin-like Protein Regulates G-Protein βγ Folding by Interaction with Tailless Complex Polypeptide-1α , 2005, Journal of Biological Chemistry.
[36] G. Nagy,et al. Differential control of adrenal and sympathetic catecholamine release by alpha 2-adrenoceptor subtypes. , 2003, Molecular endocrinology.
[37] Heinz Bönisch,et al. Comparison of in vitro and in vivo reference genes for internal standardization of real-time PCR data. , 2006, BioTechniques.
[38] Brian K. Kobilka,et al. Behavioural and cardiovascular effects of disrupting the angiotensin II type-2 receptor gene in mice , 1995, Nature.
[39] Simon C. Potter,et al. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls , 2007, Nature.
[40] E. Ritz. Total cardiovascular risk management. , 2007, The American journal of cardiology.
[41] Tianxin Yang,et al. Influence of genetic background and gender on hypertension and renal failure in COX-2-deficient mice. , 2005, American journal of physiology. Renal physiology.
[42] S. Lorkowski,et al. Cloning, cellular localization, genomic organization, and tissue-specific expression of the TGFbeta1-inducible SMAP-5 gene. , 2005, Gene.
[43] Remo Guidieri. Res , 1995, RES: Anthropology and Aesthetics.
[44] Mark Daly,et al. Haploview: analysis and visualization of LD and haplotype maps , 2005, Bioinform..
[45] T. Ogihara,et al. Identification of Hypertension-Susceptibility Genes and Pathways by a Systemic Multiple Candidate Gene Approach: The Millennium Genome Project for Hypertension , 2008, Hypertension Research.
[46] W. Wetsel,et al. Anovulation in cyclooxygenase-2-deficient mice is restored by prostaglandin E2 and interleukin-1beta. , 1999, Endocrinology.
[47] K. Reynolds,et al. Global burden of hypertension: analysis of worldwide data , 2005, The Lancet.
[48] I. Rodriguez,et al. Natural melatonin 'knockdown' in C57BL/6J mice: rare mechanism truncates serotonin N-acetyltransferase. , 1998, Brain research. Molecular brain research.
[49] Y. Benjamini,et al. Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .
[50] H. Hamm,et al. Phosducin-like protein acts as a molecular chaperone for G protein betagamma dimer assembly. , 2005, The EMBO journal.